Marth C - Search Results

1

Significant survival impact of MACC1 polymorphisms in HER2 positive breast cancer patients.

Muendlein A, Hubalek M, Geller-Rhomberg S, Gasser K, Winder T, Drexel H, Decker T, Mueller-Holzner E, Chamson M, Marth C, Lang AH. Muendlein A, et al. Among authors: marth c. Eur J Cancer. 2014 Aug;50(12):2134-41. doi: 10.1016/j.ejca.2014.05.007. Epub 2014 Jun 5. Eur J Cancer. 2014. PMID: 24910416

2

Epidermal growth factor reduces HER-2 protein level in human ovarian carcinoma cells.

Marth C, Lang T, Cronauer MV, Doppler W, Zeimet AG, Bachmair F, Ullrich A, Daxenbichler G. Marth C, et al. Int J Cancer. 1992 Sep 9;52(2):311-6. doi: 10.1002/ijc.2910520226. Int J Cancer. 1992. PMID: 1355758

3

Modulation of tumour marker CA-125 expression in cultured ovarian carcinoma cells.

Marth C, Zeimet AG, Böck G, Daxenbichler G. Marth C, et al. Eur J Cancer. 1992;28A(12):2002-6. doi: 10.1016/0959-8049(92)90248-z. Eur J Cancer. 1992. PMID: 1419298

4

The prognostic value of nuclear roundness and neopterin in ovarian cancer.

Marth C, Weger A, Müller-Holzner E, Zeimet AG, Moncayo-Naveda H, Daxenbichler G, Reibnegger G, Fuchs D, Wachter H, Dapunt O. Marth C, et al. Eur J Cancer. 1993;29A(13):1863-8. doi: 10.1016/0959-8049(93)90539-r. Eur J Cancer. 1993. PMID: 8260243

5

Circulating immunostimulatory protein 90K and soluble interleukin-2-receptor in human ovarian cancer.

Zeimet AG, Natoli C, Herold M, Fuchs D, Windbichler G, Daxenbichler G, Iacobelli S, Dapunt O, Marth C. Zeimet AG, et al. Among authors: marth c. Int J Cancer. 1996 Sep 27;68(1):34-8. doi: 10.1002/(SICI)1097-0215(19960927)68:1<34::AID-IJC7>3.0.CO;2-Y. Int J Cancer. 1996. PMID: 8895537

6

High serum levels of soluble CD44 variant isoform v5 are associated with favourable clinical outcome in ovarian cancer.

Zeimet AG, Widschwendter M, Uhl-Steidl M, Müller-Holzner E, Daxenbichler G, Marth C, Dapunt O. Zeimet AG, et al. Among authors: marth c. Br J Cancer. 1997;76(12):1646-51. doi: 10.1038/bjc.1997.611. Br J Cancer. 1997. PMID: 9413956 Free PMC article.

7

Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma.

Abendstein B, Marth C, Müller-Holzner E, Widschwendter M, Daxenbichler G, Zeimet AG. Abendstein B, et al. Among authors: marth c. Cancer. 2000 Mar 15;88(6):1432-7. doi: 10.1002/(sici)1097-0142(20000315)88:6<1432::aid-cncr22>3.0.co;2-8. Cancer. 2000. PMID: 10717627

8

Immunohistochemical determination of HER2 expression in breast cancer from core biopsy specimens: a reliable predictor of HER2 status of the whole tumor.

Mueller-Holzner E, Fink V, Frede T, Marth C. Mueller-Holzner E, et al. Among authors: marth c. Breast Cancer Res Treat. 2001 Sep;69(1):13-9. doi: 10.1023/a:1012281221647. Breast Cancer Res Treat. 2001. PMID: 11759824 Clinical Trial.

9

Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis.

Marth C, Kisic J, Kaern J, Tropé C, Fodstad Ø. Marth C, et al. Cancer. 2002 Feb 1;94(3):707-12. doi: 10.1002/cncr.10250. Cancer. 2002. PMID: 11857303 Free article.

10

[The evaluation of the second-look operation of patients with ovarian carcinoma and tubal carcinoma by means of a retrospective comparison study].

Ott HW, Illmensee K, Zeimet A, Mueller-Holzner E, Windbichler G, Eibl G, Marth C. Ott HW, et al. Among authors: marth c. Gynakol Geburtshilfliche Rundsch. 2002;42(4):217-24. doi: 10.1159/000065152. Gynakol Geburtshilfliche Rundsch. 2002. PMID: 12373026 German.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

496 results

Search Page

Filters